Skip to main content

Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis.

Publication ,  Journal Article
Pillai, M; Rajaram, G; Thakur, P; Agarwal, N; Muralidharan, S; Ray, A; Barbhaya, D; Somarelli, JA; Jolly, MK
Published in: Front Oncol
2022

Epithelial to mesenchymal transition (EMT) is a well-studied hallmark of epithelial-like cancers that is characterized by loss of epithelial markers and gain of mesenchymal markers. Melanoma, which is derived from melanocytes of the skin, also undergo phenotypic plasticity toward mesenchymal-like phenotypes under the influence of various micro-environmental cues. Our study connects EMT to the phenomenon of de-differentiation (i.e., transition from proliferative to more invasive phenotypes) observed in melanoma cells during drug treatment. By analyzing 78 publicly available transcriptomic melanoma datasets, we found that de-differentiation in melanoma is accompanied by upregulation of mesenchymal genes, but not necessarily a concomitant loss of an epithelial program, suggesting a more "one-dimensional" EMT that leads to a hybrid epithelial/mesenchymal phenotype. Samples lying in the hybrid epithelial/mesenchymal phenotype also correspond to the intermediate phenotypes in melanoma along the proliferative-invasive axis - neural crest and transitory ones. As melanoma cells progress along the invasive axis, the mesenchymal signature does not increase monotonically. Instead, we observe a peak in mesenchymal scores followed by a decline, as cells further de-differentiate. This biphasic response recapitulates the dynamics of melanocyte development, suggesting close interactions among genes controlling differentiation and mesenchymal programs in melanocytes. Similar trends were noted for metabolic changes often associated with EMT in carcinomas in which progression along mesenchymal axis correlates with the downregulation of oxidative phosphorylation, while largely maintaining glycolytic capacity. Overall, these results provide an explanation for how EMT and de-differentiation axes overlap with respect to their transcriptional and metabolic programs in melanoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2022

Volume

12

Start / End Page

913803

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pillai, M., Rajaram, G., Thakur, P., Agarwal, N., Muralidharan, S., Ray, A., … Jolly, M. K. (2022). Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis. Front Oncol, 12, 913803. https://doi.org/10.3389/fonc.2022.913803
Pillai, Maalavika, Gouri Rajaram, Pradipti Thakur, Nilay Agarwal, Srinath Muralidharan, Ankita Ray, Dev Barbhaya, Jason A. Somarelli, and Mohit Kumar Jolly. “Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis.Front Oncol 12 (2022): 913803. https://doi.org/10.3389/fonc.2022.913803.
Pillai M, Rajaram G, Thakur P, Agarwal N, Muralidharan S, Ray A, et al. Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis. Front Oncol. 2022;12:913803.
Pillai, Maalavika, et al. “Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis.Front Oncol, vol. 12, 2022, p. 913803. Pubmed, doi:10.3389/fonc.2022.913803.
Pillai M, Rajaram G, Thakur P, Agarwal N, Muralidharan S, Ray A, Barbhaya D, Somarelli JA, Jolly MK. Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis. Front Oncol. 2022;12:913803.

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2022

Volume

12

Start / End Page

913803

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis